A novel side-bridged hybrid phosphonate/acetate pendant cyclam: Synthesis, characterization, and 64Cu small animal PET imaging

被引:31
作者
Boswell, C. Andrew [1 ]
Regino, Celeste A. S. [2 ]
Baidoo, Kwamena E. [1 ]
Wong, Karen J. [2 ]
Milenic, Diane E. [1 ]
Kelley, James A. [3 ]
Lai, Christopher C. [3 ]
Brechbiel, Martin W. [1 ]
机构
[1] NCI, Radioimmune & Inorgan Chem Sect, Radiat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Imaging Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] NCI, Med Chem Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA
关键词
Positron emission tomography; Copper-64; Side-bridged cyclam; Bifunctional chelating agent; IN-VIVO; MACROCYCLIC LIGANDS; THERMODYNAMIC STABILITY; COPPER(II) COMPLEXES; MONOCLONAL-ANTIBODY; DERIVATIVES; LYMPHOMA; LYM-1; MICE; 1,4,8,11-TETRAAZACYCLOTETRADECANE;
D O I
10.1016/j.bmc.2008.11.073
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Copper-64 (t(1/2) = 12.7 h; beta(+): 0.653 MeV, 17.4%; beta: 0.578 MeV, 39%) is produced in a biomedical cyclotron and has applications in both imaging and therapy. Macrocyclic chelators are widely used as bifunctional chelators to bind copper radionuclides to antibodies and peptides owing to their relatively high kinetic stability. A novel side-bridged cyclam featuring both pendant acetate and phosphonate groups was synthesized using a Kabachnik-Fields approach followed by hydrobromic acid deprotection. The Cu(II) complex of the novel ligand was synthesized, radiolabeling with Cu-64 was demonstrated, and in vitro (serum) stability was performed. In addition, in vivo distribution and clearance of the Cu-64-labeled complex was visualized by positron emission tomography (PET) imaging. This novel chelate may be useful in Cu-64-mediated diagnostic positron emission tomography (PET) imaging as well as targeted radiotherapeutic applications. Published by Elsevier Ltd.
引用
收藏
页码:548 / 552
页数:5
相关论文
共 39 条
[1]   Radiometal labeled agents (non-technetium) for diagnostic imaging [J].
Anderson, CJ ;
Welch, MJ .
CHEMICAL REVIEWS, 1999, 99 (09) :2219-2234
[2]  
Anderson CJ, 2001, J NUCL MED, V42, P213
[3]  
Anderson CJ, 1998, J NUCL MED, V39, P1944
[4]  
ANDERSON CJ, 1995, J NUCL MED, V36, P2315
[5]   Metabolism of radiometal-labeled proteins and peptides:: What are the real radiopharmaceuticals in vivo? [J].
Anderson, CJ .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2001, 16 (06) :451-455
[6]   Radiopharmaceuticals for targeted radiotherapy of cancer [J].
Anderson, CJ ;
Lewis, JS .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2000, 10 (07) :1057-1069
[7]   In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver [J].
Bass, LA ;
Wang, M ;
Welch, MJ ;
Anderson, CJ .
BIOCONJUGATE CHEMISTRY, 2000, 11 (04) :527-532
[8]  
BELSKII FI, 1992, USP KHIM+, V61, P415
[9]   New side-bridged bismacrocycles and cross-bridged macrotricycles. Syntheses and Cu(II) complexation study [J].
Bernier, N ;
Allali, M ;
Tripier, R ;
Conan, F ;
Patinec, V ;
Develay, S ;
Le Baccon, M ;
Handel, H .
NEW JOURNAL OF CHEMISTRY, 2006, 30 (03) :435-441
[10]   Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes [J].
Boswell, CA ;
Sun, XK ;
Niu, WJ ;
Weisman, GR ;
Wong, EH ;
Rheingold, AL ;
Anderson, CJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (06) :1465-1474